Zaklina Kovacevic

List of Publications by Year
in descending order

86 papers	4,791 citations	76326 40 h-index	98798 67 g-index
91 all docs	91 docs citations	91 times ranked	5868 citing authors

#	Article	IF	Citations
1	Thiosemicarbazones from the Old to New: Iron Chelators That Are More Than Just Ribonucleotide Reductase Inhibitors. Journal of Medicinal Chemistry, 2009, 52, 5271-5294.	6.4	338
2	The Iron Chelators Dp44mT and DFO Inhibit TGF-Î²-induced Epithelial-Mesenchymal Transition via Up-Regulation of N-Myc Downstream-regulated Gene 1 (NDRG1). Journal of Biological Chemistry, 2012, 287, 17016-17028.	3.4	213
3	Tuning Cell Cycle Regulation with an Iron Key. Cell Cycle, 2007, 6, 1982-1994.	2.6	206
4	The metastasis suppressor, Ndrg-1: a new ally in the fight against cancer. Carcinogenesis, 2006, 27, 2355-2366.	2.8	168
5	Iron Chelators for the Treatment of Cancer. Current Medicinal Chemistry, 2012, 19, 2689-2702.	2.4	158
6	Novel Thiosemicarbazone Iron Chelators Induce Up-Regulation and Phosphorylation of the Metastasis Suppressor N-myc Down-Stream Regulated Gene 1: A New Strategy for the Treatment of Pancreatic Cancer. Molecular Pharmacology, 2011, 80, 598-609.	2.3	154
7	The Iron-Regulated Metastasis Suppressor NDRG1 Targets NEDD4L, PTEN, and SMAD4 and Inhibits the PI3K and Ras Signaling Pathways. Antioxidants and Redox Signaling, 2013, 18, 874-887.	5.4	151
8	Roads to melanoma: Key pathways and emerging players in melanoma progression and oncogenic signaling. Biochimica Et Biophysica Acta - Molecular Cell Research, 2016, 1863, 770-784.	4.1	148
9	Targeting cancer by binding iron: Dissecting cellular signaling pathways. Oncotarget, 2015, 6, 18748-18779.	1.8	137
10	The renaissance of polypharmacology in the development of anti-cancer therapeutics: Inhibition of the â€œTriad of Deathâ€•in cancer by Di-2-pyridylketone thiosemicarbazones. Pharmacological Research, 2015, 100, 255-260.	7.1	127
11	Metastasis suppressor, NDRG1, mediates its activity through signaling pathways and molecular motors. Carcinogenesis, 2013, 34, 1943-1954.	2.8	117
12	Redox cycling metals: Pedaling their roles in metabolism and their use in the development of novel therapeutics. Biochimica Et Biophysica Acta - Molecular Cell Research, 2016, 1863, 727-748.	4.1	111
13	The Iron Chelator, Deferasirox, as a Novel Strategy for Cancer Treatment: Oral Activity Against Human Lung Tumor Xenografts and Molecular Mechanism of Action. Molecular Pharmacology, 2013, 83, 179-190.	2.3	106
14	Copper and conquer: copper complexes of di-2-pyridylketone thiosemicarbazones as novel anti-cancer therapeutics. Metallomics, 2016, 8, 874-886.	2.4	105
15	Dp44mT targets the AKT, TGF-Î² and ERK pathways via the metastasis suppressor NDRG1 in normal prostate epithelial cells and prostate cancer cells. British Journal of Cancer, 2013, 108, 409-419.	6.4	100
16	The novel thiosemicarbazone, di-2-pyridylketone 4-cyclohexyl-4-methyl-3-thiosemicarbazone (DpC), inhibits neuroblastoma growth in vitro and in vivo via multiple mechanisms. Journal of Hematology and Oncology, 2016, 9, 98.	17.0	94
17	The metastasis suppressor, NDRG1, modulates Î²-Catenin phosphorylation and nuclear translocation by mechanisms involving FRAT1 and PAK4. Journal of Cell Science, 2014, 127, 3116-30.	2.0	93
18	Targeting the Metastasis Suppressor, NDRG1, Using Novel Iron Chelators: Regulation of Stress Fiber-Mediated Tumor Cell Migration via Modulation of the ROCK1/pMLC2 Signaling Pathway. Molecular Pharmacology, 2013, 83, 454-469.	2.3	90

#	Article	IF	Citations
19	Molecular functions of the iron-regulated metastasis suppressor, NDRG1, and its potential as a molecular target for cancer therapy. Biochimica Et Biophysica Acta: Reviews on Cancer, 2014, 1845, 1-19.	7.4	88
20	The TGF-Î², PI3K/Akt and PTEN pathways: established and proposed biochemical integration in prostate cancer. Biochemical Journal, 2009, 417, 411-421.	3.7	86
21	The Metastasis Suppressor, N-myc Downstream-regulated Gene 1 (NDRG1), Inhibits Stress-induced Autophagy in Cancer Cells. Journal of Biological Chemistry, 2014, 289, 9692-9709.	3.4	83
22	Synthesis, Characterization, and in Vitro Anticancer Activity of Copper and Zinc Bis(Thiosemicarbazone) Complexes. Inorganic Chemistry, 2019, 58, 13709-13723.	4.0	78
23	The metastasis suppressor, N-myc downstream regulated gene 1 (NDRG1), upregulates p21 via p53-independent mechanisms. Carcinogenesis, 2011, 32, 732-740.	2.8	76
24	The role of NDRG1 in the pathology and potential treatment of human cancers. Journal of Clinical Pathology, 2013, 66, 911-917.	2.0	72
25	The iron-regulated metastasis suppressor, Ndrg-1: Identification of novel molecular targets. Biochimica Et Biophysica Acta - Molecular Cell Research, 2008, 1783, 1981-1992.	4.1	70
26	The Medicinal Chemistry of Novel Iron Chelators for the Treatment of Cancer. Current Topics in Medicinal Chemistry, 2011, 11, 483-499.	2.1	69
27	The Metastasis Suppressor, N-MYC Downstream-regulated Gene-1 (NDRG1), Down-regulates the ErbB Family of Receptors to Inhibit Downstream Oncogenic Signaling Pathways. Journal of Biological Chemistry, 2016, 291, 1029-1052.	3.4	65
28	The proto-oncogene c-Src and its downstream signaling pathways are inhibited by the metastasis suppressor, NDRG1. Oncotarget, 2015, 6, 8851-8874.	1.8	64
29	The emerging role of progesterone receptor membrane component 1 (PGRMC1) in cancer biology. Biochimica Et Biophysica Acta: Reviews on Cancer, 2016, 1866, 339-349.	7.4	63
30	Synthesis and characterization of quinoline-based thiosemicarbazones and correlation of cellular iron-binding efficacy to anti-tumor efficacy. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 5527-5531.	2.2	61
31	N-myc Downstream Regulated 1 (NDRG1) Is Regulated by Eukaryotic Initiation Factor 3a (eIF3a) during Cellular Stress Caused by Iron Depletion. PLoS ONE, 2013, 8, e57273.	2.5	59
32	Metals and metastasis: Exploiting the role of metals in cancer metastasis to develop novel anti-metastatic agents. Pharmacological Research, 2017, 115, 275-287.	7.1	56
33	Expanding horizons in iron chelation and the treatment of cancer: Role of iron in the regulation of ER stress and the epithelialâ€“mesenchymal transition. Biochimica Et Biophysica Acta: Reviews on Cancer, 2014, 1845, 166-181.	7.4	50
34	Interplay of the iron-regulated metastasis suppressor NDRG1 with epidermal growth factor receptor (EGFR) and oncogenic signaling. Journal of Biological Chemistry, 2017, 292, 12772-12782.	3.4	48
35	Pharmacological targeting and the diverse functions of the metastasis suppressor, NDRG1, in cancer. Free Radical Biology and Medicine, 2020, 157, 154-175.	2.9	47
36	Targeting the Metastasis Suppressor, N-Myc Downstream Regulated Gene-1, with Novel Di-2-Pyridylketone Thiosemicarbazones: Suppression of Tumor Cell Migration and Cell-Collagen Adhesion by Inhibiting Focal Adhesion Kinase/Paxillin Signaling. Molecular Pharmacology, 2016, 89, 521-540.	2.3	45

#	Article	IF	Citations
37	Frataxin and the molecular mechanism of mitochondrial iron-loading in Friedreich's ataxia. Clinical Science, 2016, 130, 853-870.	4.3	45
38	The metastasis suppressor, NDRG1, attenuates oncogenic TGF-Î² and NF-ÎºB signaling to enhance membrane E-cadherin expression in pancreatic cancer cells. Carcinogenesis, 2019, 40, 805-818.	2.8	45
39	Siderocalin/Lcn2/NGAL/24p3 Does Not Drive Apoptosis Through Gentisic Acid Mediated Iron Withdrawal in Hematopoietic Cell Lines. PLoS ONE, 2012, 7, e43696.	2.5	45
40	Investigating the anti-proliferative activity of styrylazanaphthalenes and azanaphthalenediones. Bioorganic and Medicinal Chemistry, 2010, 18, 2664-2671.	3.0	44
41	The molecular effect of metastasis suppressors on Src signaling and tumorigenesis: new therapeutic targets. Oncotarget, 2015, 6, 35522-35541.	1.8	43
42	Investigating the Spectrum of Biological Activity of Ring-Substituted Salicylanilides and Carbamoylphenylcarbamates. Molecules, 2010, 15, 8122-8142.	3.8	40
43	The metastasis suppressor, NDRG1, inhibits â€œstemnessâ€•of colorectal cancer via down-regulation of nuclear Î²-catenin and CD44. Oncotarget, 2015, 6, 33893-33911.	1.8	40
44	Novel Mechanism of Cytotoxicity for the Selective Selenosemicarbazone, 2-Acetylpyridine 4,4-Dimethyl-3-selenosemicarbazone (Ap44mSe): Lysosomal Membrane Permeabilization. Journal of Medicinal Chemistry, 2016, 59, 294-312.	6.4	39
45	Novel Thiosemicarbazones Regulate the Signal Transducer and Activator of Transcription 3 (STAT3) Pathway: Inhibition of Constitutive and Interleukin 6â€“Induced Activation by Iron Depletion. Molecular Pharmacology, 2015, 87, 543-560.	2.3	37
46	Mechanism of the induction of endoplasmic reticulum stress by the anti-cancer agent, di-2-pyridylketone 4,4-dimethyl-3-thiosemicarbazone (Dp44mT): Activation of PERK/eIF2Î±, IRE1Î±, ATF6 and calmodulin kinase. Biochemical Pharmacology, 2016, 109, 27-47.	4.4	36
47	Identification of differential phosphorylation and sub-cellular localization of the metastasis suppressor, NDRG1. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2018, 1864, 2644-2663.	3.8	36
48	PGRMC1 regulation by phosphorylation: potential new insights in controlling biological activity. Oncotarget, 2016, 7, 50822-50827.	1.8	35
49	Lysosomal membrane stability plays a major role in the cytotoxic activity of the anti-proliferative agent, di-2-pyridylketone 4,4-dimethyl-3-thiosemicarbazone (Dp44mT). Biochimica Et Biophysica Acta - Molecular Cell Research, 2016, 1863, 1665-1681.	4.1	34
50	The metastasis suppressor NDRG1 down-regulates the epidermal growth factor receptor via a lysosomal mechanism by up-regulating mitogen-inducible gene 6. Journal of Biological Chemistry, 2019, 294, 4045-4064.	3.4	33
51	A Nitric Oxide Storage and Transport System That Protects Activated Macrophages from Endogenous Nitric Oxide Cytotoxicity. Journal of Biological Chemistry, 2016, 291, 27042-27061.	3.4	32
52	Regulation and control of nitric oxide (NO) in macrophages: Protecting the â€œprofessional killer cellâ€• from its own cytotoxic arsenal via MRP1 and GSTP1. Biochimica Et Biophysica Acta - General Subjects, 2017, 1861, 995-999.	2.4	32
53	Glutathione S-transferase and MRP1 form an integrated system involved in the storage and transport of dinitrosylâ€“dithiolato iron complexes in cells. Free Radical Biology and Medicine, 2014, 75, 14-29.	2.9	29
54	Ironing out the role of the cyclin-dependent kinase inhibitor, p21 in cancer: Novel iron chelating agents to target p21 expression and activity. Free Radical Biology and Medicine, 2019, 133, 276-294.	2.9	27

#	Article	IF	Citations
55	Unique targeting of androgenâ€dependent and â€independent AR signaling in prostate cancer to overcome androgen resistance. FASEB Journal, 2020, 34, 11511-11528.	0.5	25
56	Breaking the cycle: Targeting of NDRG1 to inhibit biâ€directional oncogenic crossâ€talk between pancreatic cancer and stroma. FASEB Journal, 2021, 35, e21347.	0.5	23
57	Novel Thiosemicarbazones Inhibit Lysine-Rich Carcinoembryonic Antigenâ€"Related Cell Adhesion Molecule 1 (CEACAM1) Coisolated (LYRIC) and the LYRIC-Induced Epithelial-Mesenchymal Transition via Upregulation of N-Myc Downstream-Regulated Gene 1 (NDRG1). Molecular Pharmacology, 2017, 91, 499-517.	2.3	22
58	Targeting Oncogenic Nuclear Factor Kappa B Signaling with Redox-Active Agents for Cancer Treatment. Antioxidants and Redox Signaling, 2019, 30, 1096-1123.	5.4	21
59	Overcoming tamoxifen resistance in oestrogen receptorâ€positive breast cancer using the novel thiosemicarbazone antiâ€cancer agent, <scp>DpC</scp>. British Journal of Pharmacology, 2020, 177, 2365-2380.	5.4	21
60	Targeting Wnt/tenascin C-mediated cross talk between pancreatic cancer cells and stellate cells via activation ofÂtheÂmetastasis suppressor NDRG1. Journal of Biological Chemistry, 2022, 298, 101608.	3.4	20
61	Exploiting Cancer Metal Metabolism using Anti-Cancer Metal- Binding Agents. Current Medicinal Chemistry, 2019, 26, 302-322.	2.4	19
62	Thiosemicarbazones suppress expression of the c-Met oncogene by mechanisms involving lysosomal degradation and intracellular shedding. Journal of Biological Chemistry, 2020, 295, 481-503.	3.4	18
63	The metastasis suppressor NDRG1 directly regulates androgen receptor signaling in prostate cancer. Journal of Biological Chemistry, 2021, 297, 101414.	3.4	18
64	Making a case for albumin â€" a highly promising drug-delivery system. Future Medicinal Chemistry, 2015, 7, 553-556.	2.3	17
65	Iron Chelation: Inhibition of Key Signaling Pathways in the Induction of the Epithelial Mesenchymal Transition in Pancreatic Cancer and Other Tumors. Critical Reviews in Oncogenesis, 2013, 18, 409-434.	0.4	15
66	Differential targeting of the cyclin-dependent kinase inhibitor, p21CIP1/WAF1, by chelators with anti-proliferative activity in a range of tumor cell-types. Oncotarget, 2015, 6, 29694-29711.	1.8	15
67	Iron Chelators: Development of Novel Compounds with High and Selective Anti-Tumour Activity. Current Drug Delivery, 2010, 7, 194-207.	1.6	14
68	Two mechanisms involving the autophagic and proteasomal pathways process the metastasis suppressor protein, N-myc downstream regulated gene 1. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2019, 1865, 1361-1378.	3.8	12
69	E6AP Promotes a Metastatic Phenotype in Prostate Cancer. IScience, 2019, 22, 1-15.	4.1	11
70	Transcriptional regulation of the cyclin-dependent kinase inhibitor, p21 CIP1/WAF1 , by the chelator, Dp44mT. Biochimica Et Biophysica Acta - General Subjects, 2018, 1862, 761-774.	2.4	10
71	Copper that cancer with lysosomal love!. Aging, 2016, 8, 210-211.	3.1	10
72	Tumor-induced neoangiogenesis and receptor tyrosine kinases â€" Mechanisms and strategies for acquired resistance. Biochimica Et Biophysica Acta - General Subjects, 2019, 1863, 1217-1225.	2.4	9

#	Article	IF	Citations
73	Chelators to the Rescue: Different Horses for Different Courses!. Chemical Research in Toxicology, 2011, 24, 279-282.	3.3	8
74	Research Spotlight: Iron chelation: deciphering novel molecular targets for cancer therapy. The tip of the iceberg of a web of iron-regulated molecules. Future Medicinal Chemistry, 2011, 3, 1983-1986.	2.3	5
75	The redox-active, anti-cancer drug Dp44mT inhibits T-cell activation and CD25 through a copper-dependent mechanism. Redox Report, 2013, 18, 48-50.	4.5	3
76	Targeting Iron in Cancer Cells: A New Strategy to Inhibit Metastatic Progression. , 2012, 01, .		2
77	Abstract A67: Mechanisms involved in regulating the expression of the cyclin-dependent kinase (cdk) inhibitor, p21, by intracellular iron levels.. , 2011, , .		1
78	Targeting autophagy in antitumor agent design: furthering the â€˜lysosomal loveâ€™ strategy. Future Medicinal Chemistry, 2016, 8, 727-729.	2.3	0
79	Abstract B172: The metastasis suppressor NDRG1 upâ€•regulates p21 in a p53â€•independent manner in cancer cells: A novel insight into its antitumor function. , 2009, , .		0
80	Targeting the Metastasis Suppressor NDRG1: A New Strategy for the Treatment of Pancreatic Cancer. FASEB Journal, 2012, 26, 761.28.	0.5	0
81	Abstract A232: Novel thiosemicarbazones with potent antitumor and antimetastatic activity inhibit the signal transducer and activator of transcription (STAT) pathway.. , 2013, , .		0
82	Abstract A63: Role of the metastasis suppressor, NDRG1, in regulating the EGFR and ErbB family of receptors and its effects on key oncogenic signaling pathways in pancreatic cancer. , 2015, , .		0
83	Abstract A165: Novel thiosemicarbazone, Dp44mT, promotes NDRG1 to downregulate oncogenic signaling pathways in cancer. , 2018, , .		0
84	Abstract B212: N-myc downstream regulated 1 (NDRG1) is regulated by eukaryotic initiation factor 3a (eIF3a) during cellular stress caused by iron depletion. , 2018, , .		0
85	Abstract A16: A novel therapeutic approach to inhibit the bidirectional oncogenic crosstalk between pancreatic cancer cells and the surrounding stroma. , 2019, , .		0
86	Abstract P2-04-02: Progesterone receptor membrane component 1 - A novel key regulator in lipid homeostasis drives oncogenic signaling resulting in breast cancer progression. , 2020, , .		0